Maintain pressure on reforms to protect NHSArthritis treatment increases gastrointestinal complications
Arthritis patients receiving a non-selective non-steroidal anti-inflammatory drug, plus a proton pump inhibitor, are more than four times more likely to suffer adverse gastrointestinal clinical outcomes than those who receive a cyclo-oxygenase-2 selective NSAID, according to international researchers.
Their study involved 4,484 patients, with either osteoarthritis or rheumatoid arthritis, who were randomly allocated to treatment with the COX-2 celecoxib or the NSAID diclofenac plus omeprazole.
The results were presented last week at the European League Against Rheumatism annual conference in Rome and published online in The Lancet.
Have your say
You must sign in to make a comment.
Online training units, written and reviewed by experts. Earn two hours' CPD and a personalised certificate for your portfolio.
Subscribers get five FREE learning units and non-subscribers can access each learning unit for £10 + VAT.
Share
Readers' comments (1)
Anonymous | 27-Jun-2010 12:24 pm
I was taking Celebrex a few years ago but it was withdrawn. I can't remember why but is it now deemed safe to use?
Unsuitable or offensive?